Skip to main content
Fig. 1 | Trials

Fig. 1

From: Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial

Fig. 1

Study design. Note timeline between visits: Visits 1 and 2: ≤ 14 days. Can also occur on the same day and thus data from screening visit does not need to be replicated at visit 2. Visits 2 and 3: ≥ 2 days and ≤ 7 days. Visit 3 and visit 4 and visit 5 and visit 6: ≥ 2 days. Visit 6 and visit 7: ≥ 3 days

Back to article page

Trials

ISSN: 1745-6215